EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Toripalimab and Penpulimab: Targeting PD-1 in Recurrent or Metastatic Nasopharyngeal Carcinoma

Josie J Hockett, Molly E Keller, David J Reeves iD

Annals of Pharmacotherapy · 2026

DOI: 10.1177/10600280251391430 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Annals of Pharmacotherapy, 2026. Verfasst von Josie J Hockett und 2 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy and Health Sciences, Butler University, Indianapolis, IN, USA. Hauptthemen laut MEDLINE: Nasopharyngeal Carcinoma, Antibodies, Monoclonal, Humanized, Nasopharyngeal Neoplasms, Programmed Cell Death 1 Receptor. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The objective of this review is to evaluate clinical data regarding use of toripalimab and penpulimab use in recurrent or metastatic nasopharyngeal carcinoma (RM-NPC) and to assess their impact on patient care. Data sources: A literature search of PubMed, Cochrane library, and clinicaltrials.gov was performed using toripalimab, Loqtorzi, JS001 , penpulimab , and AK105 . Study selection and data extraction: Inclusion was limited to English-language publications evaluating toripalimab and penpulimab for RM-NPC management. Data synthesis: Toripalimab and penpulimab are the first US Food and Drug Administration (FDA)-approved immune checkpoint inhibitors for RM-NPC. Both agents block the PD-1/PD-L1 interaction between tumor and T cells, enhancing anti-tumor immune responses. In the first-line setting, toripalimab plus chemotherapy achieved a median progression-free survival (PFS) of 21.4 months and overall response rate (ORR) of 78.8%. Penpulimab plus chemotherapy demonstrated a median PFS of 9.6 months and ORR of 68.1%. Toripalimab/chemotherapy was associated with an improved overall survival (hazard ratio [HR] = 0.63, P = .008); penpulimab/chemotherapy overall survival data were not yet mature. As monotherapies, ORRs were 20.5% for toripalimab and 28.0% for penpulimab. Common adverse effects include immune-related adverse effects such as hypothyroidism and rash. Relevance to patient care and clinical practice in comparison to existing drugs: These agents offer crucial new therapeutic options for RM-NPC, previously managed primarily with chemotherapy. The data supporting toripalimab use are currently more mature; however, penpulimab may offer an alternative for patients unable to tolerate cisplatin due being studied in combination with carboplatin.

Conclusion

Toripalimab and penpulimab significantly improve outcomes in RM-NPC. Their use is anticipated to expand into additional settings and malignancies as research matures.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Nasopharyngeal CarcinomaAntibodies, Monoclonal, HumanizedNasopharyngeal NeoplasmsProgrammed Cell Death 1 ReceptorNeoplasm Recurrence, LocalImmune Checkpoint InhibitorsBenzamidesHumansAntineoplastic Combined Chemotherapy Protocols

Stichwörter der Autor:innen

immune checkpoint inhibitornasopharyngeal carcinomapenpulimabtoripalimab

Substanzen

Antibodies, Monoclonal, HumanizedProgrammed Cell Death 1 ReceptortoripalimabImmune Checkpoint InhibitorsPDCD1 protein, humanBenzamidespenpulimab

Autor:innen und Institutionen

  • College of Pharmacy and Health Sciences, Butler University, Indianapolis, IN, USA.
  • Franciscan Health Indianapolis, Indianapolis, IN, USA.

ORCID-Profile: David J Reeves

Zitieren

APA

Hockett, J. J., Keller, M. E., & Reeves, D. J. (2026). Toripalimab and Penpulimab: Targeting PD-1 in Recurrent or Metastatic Nasopharyngeal Carcinoma. Annals of Pharmacotherapy. https://doi.org/10.1177/10600280251391430

Vancouver

Hockett JJ, Keller ME, Reeves DJ. Toripalimab and Penpulimab: Targeting PD-1 in Recurrent or Metastatic Nasopharyngeal Carcinoma. Annals of Pharmacotherapy. 2026. doi:10.1177/10600280251391430

BibTeX
@article{Hockett2026,
  author = {Hockett, Josie J and Keller, Molly E and Reeves, David J},
  title = {Toripalimab and Penpulimab: Targeting PD-1 in Recurrent or Metastatic Nasopharyngeal Carcinoma},
  journal = {Annals of Pharmacotherapy},
  year = {2026},
  doi = {10.1177/10600280251391430}
}
Kostenlos starten →